bioMerieux Opens a Subsidiary in the Middle East, Continuing its International Growth
bioMérieux announced the opening of a subsidiary in the United Arab Emirates. A hub for its operations in the Middle East, bioMérieux’s 39th subsidiary will be based in Dubai. Active in the region for more than 25 years, bioMérieux has established a leading position in the United Arab Emirates diagnostics market, according to the company, through its exclusive distributor, Al Hayat Pharmaceuticals, with whom it will continue to work closely.
"This new subsidiary will be the hub for our Middle East commercial team. With 20,000 healthcare professionals in Dubai HealthCare City and international centers of excellence such as Harvard Medical School and Mayo Clinic, there are exciting opportunities in the UAE health economy," said Stéphane Bancel, Chief Executive Officer of bioMérieux. "bioMérieux’s solid business model allows us to continue our international expansion, a key factor for future growth and sales diversification."
Dubai HealthCare City, where the bioMérieux subsidiary is located, has the ambition of becoming the leading center in the region, filling a gap in healthcare services in the zone between Europe and Southeast Asia. bioMérieux will bring, in particular, its expertise as a world leader in diagnostics for healthcare associated infections (HAI) to local hospitals and universities to build HAI management programs.
Other news from the department business & finance
